The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.

The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver - The Pan Asia-Pacific Prospective Multi-centre Observational Study (APCOLIS STUDY)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04345640

Enrollment

1000

Registered

2020-04-14

Start date

2020-04-10

Completion date

2020-12-31

Last updated

2020-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhoses

Brief summary

To address the existing deficiencies in the knowledge regarding liver involvement and spectrum of clinical presentation and the impact of COVID-19 infection in patients of liver disease was planned. The present study will be a hospital based and the cases of confirmed COVID-19 infection will be evaluated in relation to liver involvement irrespective of pre-existing liver disease. The primary objective was to address the clinical presentation, biochemical alteration and outcomes of COVID-19 infection in subjects with chronic hepatitis, cirrhosis in comparison to those having infection in the absence of pre-existing liver disease

Interventions

OTHERno intervention

no intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. All patients of COVID-19 positive 2. Age 18-70 years

Exclusion criteria

1. No Valid consent

Design outcomes

Primary

Measure	Time frame
Spontaneous recovery or death in both groups	90 days

Secondary

Measure	Time frame
Duration of prior as well as present decompensation in both groups	90 days
Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups	90 days
Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups	90 days
Severity of prior as well as present decompensation in both groups	90 days
Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups	90 days
Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.	90 days
Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups	90 days

Countries

India

Contacts

Primary ContactDr Ashok Choudhary, DM

akchoudhury@ilbs.in01146300000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026